These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34863529)

  • 1. Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments.
    Dabbous M; Toumi M; Simoens S; Wasem J; Saal G; Wang Y; Osuna JLH; François C; Annemans L; Graf von der Schulenburg JM; Sola-Morales O; Malone D; Garrison LP
    Health Policy; 2022 Jan; 126(1):49-59. PubMed ID: 34863529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of amortization of gene therapies funding on the results and conclusions of CEMs and BIMs.
    Polek H; Janik J; Paterak E; Dabbous M; Pochopień M; Toumi M
    J Mark Access Health Policy; 2023; 11(1):2232648. PubMed ID: 37440980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Confronting High Costs And Clinical Uncertainty: Innovative Payment Models For Gene Therapies.
    Horrow C; Kesselheim AS
    Health Aff (Millwood); 2023 Nov; 42(11):1532-1540. PubMed ID: 37931198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost approach of health care entity intangible asset valuation.
    Reilly RF
    J Health Care Finance; 2012; 39(2):1-36. PubMed ID: 23971139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breaking the Bank: Three Financing Models for Addressing the Drug Innovation Cost Crisis.
    Kleinke JD; McGee N
    Am Health Drug Benefits; 2015 May; 8(3):118-26. PubMed ID: 26085900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact of rare diseases: proposal for a theoretical framework based on evidence from Bulgaria.
    Iskrov G; Jessop E; Miteva-Katrandzhieva T; Stefanov R
    Georgian Med News; 2015 May; (242):46-53. PubMed ID: 26042447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapies: the challenge of super-high-cost treatments and how to pay for them.
    Carr DR; Bradshaw SE
    Regen Med; 2016 Jun; 11(4):381-93. PubMed ID: 27185544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a stakeholder survey.
    Tordrup D; Angelis A; Kanavos P
    Appl Health Econ Health Policy; 2013 Dec; 11(6):639-52. PubMed ID: 24129648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managed Entry Agreements: Policy Analysis From the European Perspective.
    Dabbous M; Chachoua L; Caban A; Toumi M
    Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to develop cost-conscious guidelines.
    Eccles M; Mason J
    Health Technol Assess; 2001; 5(16):1-69. PubMed ID: 11427188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insurance switching and mismatch between the costs and benefits of new technologies.
    Cutler D; Ciarametaro M; Long G; Kirson N; Dubois R
    Am J Manag Care; 2017 Dec; 23(12):750-757. PubMed ID: 29261241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reasons to value the health care intangible asset valuation.
    Reilly RF
    J Health Care Finance; 2012; 39(2):37-51. PubMed ID: 23971140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of the economic downturn on healthcare in Spain: consequences and alternatives.
    Antonanzas F
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):433-9. PubMed ID: 23977971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies.
    Coyle D; Durand-Zaleski I; Farrington J; Garrison L; Graf von der Schulenburg JM; Greiner W; Longworth L; Meunier A; Moutié AS; Palmer S; Pemberton-Whiteley Z; Ratcliffe M; Shen J; Sproule D; Zhao K; Shah K
    Eur J Health Econ; 2020 Dec; 21(9):1421-1437. PubMed ID: 32794011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discounting in cost-utility analysis of healthcare interventions: reassessing current practice.
    Cohen BJ
    Pharmacoeconomics; 2003; 21(2):75-87. PubMed ID: 12515570
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.